JP2010235612A5 - - Google Patents

Download PDF

Info

Publication number
JP2010235612A5
JP2010235612A5 JP2010109145A JP2010109145A JP2010235612A5 JP 2010235612 A5 JP2010235612 A5 JP 2010235612A5 JP 2010109145 A JP2010109145 A JP 2010109145A JP 2010109145 A JP2010109145 A JP 2010109145A JP 2010235612 A5 JP2010235612 A5 JP 2010235612A5
Authority
JP
Japan
Prior art keywords
compound
arylcarbonylamino
alkoxy
pharmaceutically acceptable
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010109145A
Other languages
English (en)
Japanese (ja)
Other versions
JP5175316B2 (ja
JP2010235612A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2010235612A publication Critical patent/JP2010235612A/ja
Publication of JP2010235612A5 publication Critical patent/JP2010235612A5/ja
Application granted granted Critical
Publication of JP5175316B2 publication Critical patent/JP5175316B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2010109145A 2002-11-01 2010-05-11 転写因子調節化合物およびその使用方法 Expired - Fee Related JP5175316B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US42331902P 2002-11-01 2002-11-01
US60/423,319 2002-11-01
US42591602P 2002-11-13 2002-11-13
US60/425,916 2002-11-13

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004550495A Division JP2006513162A (ja) 2002-11-01 2003-11-03 転写因子調節化合物およびその使用方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012039805A Division JP2012131813A (ja) 2002-11-01 2012-02-27 転写因子調節化合物およびその使用方法

Publications (3)

Publication Number Publication Date
JP2010235612A JP2010235612A (ja) 2010-10-21
JP2010235612A5 true JP2010235612A5 (enExample) 2012-04-12
JP5175316B2 JP5175316B2 (ja) 2013-04-03

Family

ID=32314482

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004550495A Pending JP2006513162A (ja) 2002-11-01 2003-11-03 転写因子調節化合物およびその使用方法
JP2010109145A Expired - Fee Related JP5175316B2 (ja) 2002-11-01 2010-05-11 転写因子調節化合物およびその使用方法
JP2012039805A Pending JP2012131813A (ja) 2002-11-01 2012-02-27 転写因子調節化合物およびその使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004550495A Pending JP2006513162A (ja) 2002-11-01 2003-11-03 転写因子調節化合物およびその使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012039805A Pending JP2012131813A (ja) 2002-11-01 2012-02-27 転写因子調節化合物およびその使用方法

Country Status (5)

Country Link
EP (1) EP1558341A4 (enExample)
JP (3) JP2006513162A (enExample)
AU (1) AU2003291226B2 (enExample)
CA (1) CA2504448C (enExample)
WO (1) WO2004041209A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1462105A1 (en) * 2003-03-28 2004-09-29 Procorde GmbH Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases
US7132440B2 (en) 2003-04-17 2006-11-07 Janssen Pharmaceutica, N.V. Substituted benzimidazoles and imidazo-[4,5]-pyridines
EP1742637A4 (en) * 2004-04-23 2011-06-08 Paratek Pharm Innc TRANSCRIPTION FACTOR MODULATION COMPOUNDS AND METHODS OF USE
WO2007016292A2 (en) * 2005-07-27 2007-02-08 Vertex Pharmaceuticals Incorporated Heterocyclic amides as biofilm modulators
CA2617123C (en) * 2005-08-12 2015-05-26 United States Government As Represented By The Secretary Of The United States Army And The U.S. Army Medical Research & Materiel Command Broad spectrum antibacterial compounds
US20070178054A1 (en) * 2005-11-09 2007-08-02 Madhyastha Srinivasa Oral antimicrobial composition
CA2656157A1 (en) * 2006-06-23 2008-10-30 Paratek Pharmaceuticals, Inc. Transcription factor modulating compounds and methods of use thereof
EP2939687A1 (en) 2006-12-01 2015-11-04 Laclede, Inc. Use of hydrolytic enzymes to dissolve biofilm in ears
US20090131481A1 (en) * 2007-03-27 2009-05-21 Paratek Pharmaceuticals, Inc. Transcription Factor Modulating Compounds and Methods of Use Thereof
EP2000140A1 (en) 2007-06-05 2008-12-10 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo[3,2-a]pyrimidine or of 3-oxo-2,3-dihydro-5H-imidazolo[3,2-a]pyrimidine for the preparation of pharmaceutical compositions intended for the treatment of cancer
US8618300B2 (en) * 2008-09-04 2013-12-31 Boehringer Ingelheim International Gmbh Indolizine inhibitors of leukotriene production
GB0821913D0 (en) 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
US20110059962A1 (en) * 2009-04-22 2011-03-10 Alekshun Michael N Transcription factor modulating compounds and methods of use thereof
ES2803556T3 (es) * 2010-06-01 2021-01-27 Summit Oxford Ltd Compuestos para el tratamiento de enfermedades asociadas a clostridium difficile
WO2011151617A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151619A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151620A1 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile associated disease
WO2011151618A2 (en) 2010-06-01 2011-12-08 Summit Corporation Plc Compounds for the treatment of clostridium difficile-associated disease
US9382226B2 (en) * 2010-07-21 2016-07-05 Merck Sharp & Dohme Corp. Aldosterone synthase inhibitors
CN105394046B (zh) 2010-10-25 2019-03-01 范德比尔特大学 用于抑制昆虫宿主感觉的组合物
PT2705345E (pt) * 2011-05-02 2015-06-17 Lapenna José Carlos Utilização de halogeno-cianoacetamidas para fixação e preservação de amostras biológicas
WO2012154403A2 (en) 2011-05-06 2012-11-15 Vanderbilt University Composition for inhibition of insect sensing
US9079935B2 (en) 2012-08-13 2015-07-14 The Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Las Vegas Reducing risk of contracting Clostridium-difficile associated disease
ITMI20132192A1 (it) * 2013-12-23 2015-06-24 Purisa S R L Composti antimicrobici
US20180000793A1 (en) 2015-02-06 2018-01-04 Ernesto Abel-Santos Inhibiting Germination of Clostridium Perfringens Spores to Reduce Necrotic Enteritis
CN113749102A (zh) 2015-03-25 2021-12-07 范德比尔特大学 作为orco介导的气味感觉干扰剂的二元组合物
EP3380195B1 (en) 2016-01-08 2020-12-09 Institute for Systems Biology Methods to identify antituberculosis compounds
MA50256A (fr) 2017-09-15 2020-07-22 Aduro Biotech Inc Composés de pyrazolopyrimidinone et leurs utilisations
CN114127056A (zh) 2019-07-17 2022-03-01 萨米特(牛津)有限公司 制备ridinilazole及其晶型的方法
JP7458622B2 (ja) * 2019-09-18 2024-04-01 学校法人東京農業大学 抗生物質耐性微生物の耐性を低下させる物質及び抗生物質耐性微生物の耐性を低下させる方法
CN110840897B (zh) * 2019-11-28 2023-08-08 河北旺发生物科技有限公司 金属β-内酰胺酶抑制剂
CN111166743B (zh) * 2020-01-02 2022-03-22 中国医学科学院医药生物技术研究所 一类含噻唑结构化合物的抗感染用途
GB202100470D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Solid tablet dosage for of ridinilazole
GB202100471D0 (en) 2021-01-14 2021-03-03 Summit Oxford Ltd Preparation of antibacterial compounds
WO2023039159A2 (en) 2021-09-09 2023-03-16 Abel Santos Ernesto Inhibitors of c. difficile spore germination

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3300505A (en) * 1964-12-07 1967-01-24 Ciba Geigy Corp Ether-2-r-substituted benzimidazoles and derivatives and acid addition salts thereof
US3429890A (en) * 1964-12-31 1969-02-25 Merck & Co Inc Certain 2-thiazolylbenzimidazole-1-oxy derivatives
US3325356A (en) * 1965-08-20 1967-06-13 Merck & Co Inc Compositions and method for treating helminthiasis
GB1141936A (en) * 1966-03-26 1969-02-05 Shionogi & Co Improvements in or relating to benzimidazole derivatives
DE1923481A1 (de) * 1969-05-08 1970-11-12 Hoechst Ag Verfahren zur Herstellung von Amiden und Estern der 1-Hydroxy-benzimidazol-2-carbonsaeure
US3686110A (en) * 1970-02-27 1972-08-22 Meuch & Co Inc 1-oxybenzimidazoles
US3873558A (en) * 1970-03-05 1975-03-25 Merck & Co Inc Process for preparing 1,5-substituted or 1,6-substituted benzimidazoles
CH556868A (de) * 1970-03-05 1974-12-13 Merck & Co Inc Verfahren zur herstellung von 1-hydroxy-5-(oder 6-)-carbonyl-amino-2-(4'-thiazolyl)-benzimidazolen.
US3646049A (en) * 1970-03-05 1972-02-29 Merck & Co Inc Acylaminobenzimidazole derivatives
NZ221729A (en) * 1986-09-15 1989-07-27 Janssen Pharmaceutica Nv Imidazolyl methyl-substituted benzimidazole derivatives and pharmaceutical compositions
CA2002859C (en) * 1988-11-29 1998-12-29 Jean P. F. Van Wauwe Method of treating epithelial disorders
EP0973513A4 (en) * 1996-10-23 2003-03-19 Zymogenetics Inc COMPILATIONS AND METHOD FOR TREATING BONE DEFICIENCY
AU760020B2 (en) * 1998-08-31 2003-05-08 Merck & Co., Inc. Novel angiogenesis inhibitors
AU2002367953C1 (en) * 2001-05-04 2009-02-19 Paratek Pharmaceuticals, Inc Transcription factor modulating compounds and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2010235612A5 (enExample)
JP2008542291A5 (enExample)
JP2014167027A5 (enExample)
ES2579855T3 (es) Compuestos de imidazopiridinil-aminopiridina sustituidos
CN109311852A (zh) 作为egfr抑制剂的苯胺嘧啶化合物的结晶
WO2008042240A3 (en) Enantiomerically pure phosphoindoles as hiv inhibitors
HRP20140950T1 (hr) Novi spojevi i pripravci, te postupci njihove primjene
JP2016501250A5 (enExample)
SI2935307T1 (en) Non-reactive 19-alkoxy-17-substituted steroids useful in therapeutic procedures
JP2013531029A5 (enExample)
JP2014500861A5 (enExample)
JP2008531599A5 (enExample)
JP2007231005A5 (enExample)
JP2013544276A5 (enExample)
JP2013527242A5 (enExample)
JP2015524019A5 (enExample)
EA201700230A1 (ru) Определенные аминопиридины, композиции на их основе и способы их применения
JP2013545785A5 (enExample)
JP2013544860A5 (enExample)
CN109563060A (zh) Ido1抑制剂及其制备方法和应用
JP2009525287A5 (enExample)
JP2016528273A5 (enExample)
JP2015500842A5 (enExample)
JP2010536821A5 (enExample)
JP2015526454A5 (enExample)